Craneware plc

("Craneware" or the "Company")

Exercise of Share Options

21 September 2022 - The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 20 September 2022, Keith Neilson, CEO of the Company, net* exercised options over 2,664 ordinary shares of 1p each in the Company ("Ordinary Shares") at an exercise price of 400 pence per Ordinary Share.

Following the net* exercise of these share options, Mr. Neilson holds 3,434,186 Ordinary Shares in the capital of the Company, representing 9.66% of the Company's issued share capital.

*net of settlement of the exercise cost, income tax and national insurance contributions

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.   Details of the Restricted Person / person closely associated with him or her

a) Name                                                            Keith Neilson

2.   Reason for the notification

a) Position / status                                            CEO

b) Initial notification / Amendment                       Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name                                                            Craneware plc

b) LEI                                                                213800O2CTJ1YFXNXG05

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of

instrument                                                         Ordinary Shares of 1p each in the capital of Craneware plc

b) Identification code                                         ISIN GB00B2425G68

c) Nature of the transaction                                Exercise of options over Ordinary Shares

(on a net basis, after settlement of the exercise cost and tax liabilities)

d) Price(s) and volume(s)                                   Volume(s)  2,664, Price(s) £4.00

e) Aggregated information:                                N/A (single transaction)

                                    i. Aggregated volume                -

                                    ii. Price                                     -

f) Date of the transaction                                  2022-09-20

g) Place of the transaction                                 Outside a trading venue

For further information, please contact:

Craneware plc                                                                                      +44 (0)131 550 3100

Keith Neilson, CEO

Craig Preston, CFO

Alma (Financial PR)                                                                             +44 (0)20 3405 0205

Caroline Forde, Hilary Buchanan, Joe Pederzolli                                      craneware@almapr.co.uk

Peel Hunt (NOMAD and Joint Broker)                                                   +44 (0)20 7418 8900

Dan Webster, Andrew Clark

Investec Bank PLC (Joint Broker)                                                         +44 (0)20 7597 5970

Patrick Robb, Henry Reast, Sebastian Lawrence

Berenberg (Joint Broker)                                                                      +44 (0)20 3207 7800

Mark Whitmore, Richard Andrews, Alix Mecklenburg-Solodkoff

About Craneware

We at The Craneware Group of companies, including our latest additions Sentry Data Systems and Agilum Healthcare Intelligence, passionately believe we can impact healthcare profoundly by delivering the insights healthcare organisations need to also transform the business of healthcare. Our shared vision is to be the operational and financial partner for US healthcare providers.

Our combined suite of applications and industry-leading team of experts help our customers contextualise operational, financial, and clinical data, providing insights that clearly demonstrate what great looks like. These value cycle insights deliver revenue integrity and 340B compliance, as well as margin and operational intelligence- something no other single partner can provide.

Together, approximately 40% of registered US hospitals are now our customers, including more than 12,000 US hospitals, health systems and affiliated retail pharmacies and clinics. Our customers are operating with a financial impact of nearly half a trillion dollars. We have data sets from customers covering more than 150 million unique patients encounters.

Learn more at www.thecranewaregroup.com